Acute-on-Chronic Liver Failure – Allogeneic
We are recruiting patients with acute-on-chronic liver failure (ACLF) for a multicentric phase I/IIa clinical trial.
The aim of the trial is to examine the efficacy and safety of allogeneic ABCB5-positive mesenchymal stem cells (ABCB5+ MSCs) in patients suffering from ACLF. Primary endpoints are the improvement of liver function and function of other affected organs (as measured by change of the MELD score) and the occurrence of adverse events.
For this trial 18 patients will be recruited at three sites in Germany.
For the manufacturing process of the allogeneic ABCB5+ MSCs we are using a patent hold by the Brigham and Women’s Hospital, Boston/USA, and the Children’s Hospital, Boston/USA, in cooperation with our scientific partner Prof. Dr. Markus Frank.
Background information about the use of ABCB5+ MSCs in ACLF can be found HERE.